DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “hold” rating restated by stock analysts at Robert W. Baird in a research note issued on Sunday, September 10th. They presently have a $79.00 target price on the medical device company’s stock. Robert W. Baird’s price target suggests a potential upside of 12.49% from the stock’s previous close.
DXCM has been the topic of a number of other research reports. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Cowen and Company reaffirmed a “buy” rating and issued a $90.00 target price on shares of DexCom in a research note on Friday, July 14th. BMO Capital Markets reaffirmed a “buy” rating and issued a $105.00 target price on shares of DexCom in a research note on Thursday, July 13th. Piper Jaffray Companies reissued an “overweight” rating and set a $87.00 price target on shares of DexCom in a research note on Friday, September 8th. Finally, TheStreet raised DexCom from a “d” rating to a “c-” rating in a research note on Wednesday, August 2nd. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $86.87.
DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same quarter in the previous year, the firm posted ($0.24) EPS. The firm’s quarterly revenue was up 24.3% on a year-over-year basis.
TRADEMARK VIOLATION WARNING: “DexCom’s (DXCM) “Hold” Rating Reiterated at Robert W. Baird” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/dexcom-inc-dxcm-receives-hold-rating-from-robert-w-baird/1628921.html.
In other news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $78.19, for a total transaction of $113,375.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total transaction of $123,050.10. Following the transaction, the executive vice president now directly owns 72,395 shares in the company, valued at approximately $5,448,447.70. The disclosure for this sale can be found here. Insiders have sold 26,223 shares of company stock valued at $1,881,249 over the last 90 days. Insiders own 1.70% of the company’s stock.
Several large investors have recently made changes to their positions in the business. Advisor Group Inc. increased its stake in shares of DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new position in shares of DexCom during the first quarter valued at approximately $164,000. IFP Advisors Inc increased its stake in shares of DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 568 shares during the period. Independent Portfolio Consultants Inc. increased its stake in shares of DexCom by 0.4% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after acquiring an additional 9 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in shares of DexCom by 475.0% during the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after acquiring an additional 1,900 shares during the period.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.